US court upholds FDA's grant of five-year NCE exclusivity for Shire's Vyvanse
08 March 2010
Nancy Faigen
A US district court judge has upheld an FDA decision to grant five years of market exclusivity to
Shire's attention deficit/hyperactivity disorder (ADHD) drug, Vyvanse (lisdexamfetamine dimesilate), following a challenge by generics maker Actavis.
In a March 4th memorandum opinion which followed...
Please Login to read the full article.
08 March 2010
Nancy Faigen
In a March 4th memorandum opinion which followed...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Supreme Court to weigh generic drug liability, patent burden-of-proof standards
- US Capitol Capsule: Group proposes efforts to ensure US innovation competitiveness
- Shire ADHD alliance gives more power to Shionogi's diversifying lineup
- Positive Ph III data may mark start of European push in ADHD for Shire
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
